Hudson Bay Capital Management
AKCA

Hudson Bay Capital Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Hudson Bay Capital Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-35,000
Closed -$1.23M – 979
2018
Q3 		$1.23M Buy
+35,000
New +$1.06M 0.02% 549

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

Hudson Bay Capital Management's AKCA Position: Q3 2019 in Review

Hudson Bay Capital Management sold out of Akcea Therapeutics Inc (AKCA) in Q3 2019, closing a stake of 80,000 shares — an estimated $1.88M sold.

Hudson Bay Capital Management first reported a position in AKCA in Q1 2019 and held it in 2 quarters. The position peaked at $1.88M in Q2 2019. 62 funds tracked by Wall St. Rank hold AKCA as of Q3 2019.

  • Hudson Bay Capital Management reported no remaining Akcea Therapeutics Inc position as of Q3 2019 after selling out during the quarter.
  • Hudson Bay Capital Management sold 80,000 Akcea Therapeutics Inc shares in Q3 2019, an estimated $1.88M.
  • Hudson Bay Capital Management first reported a position in Akcea Therapeutics Inc in Q1 2019 and held it in 2 quarters.
  • Hudson Bay Capital Management's Akcea Therapeutics Inc position peaked at $1.88M in Q2 2019.
  • 62 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2019.

Based on Hudson Bay Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.